

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person* <u>Beyer Pat</u> (Last) (First) (Middle) <u>C/O CONMED CORPORATION</u> <u>11311 CONCEPT BOULEVARD</u> (Street) <u>LARGO FL 33773</u> (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>CONMED Corp [CNMD]</u>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner <input checked="" type="checkbox"/> Officer (give title below) Other (specify below) <u>President Int'l & Global Ortho</u>
	3. Date of Earliest Transaction (Month/Day/Year) <u>10/29/2021</u>	
4. If Amendment, Date of Original Filed (Month/Day/Year)		

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	10/29/2021		M		55,300	A	\$39.87	63,107	D	
Common Stock	10/29/2021		F		30,018	D	\$144.62	33,089	D	
Common Stock	10/29/2021		S		2,789	D	\$144.497 ⁽¹⁾	30,300	D	
Common Stock	10/29/2021		S		16,904	D	\$145.307 ⁽²⁾	13,396	D	
Common Stock	10/29/2021		S		5,589	D	\$146.135 ⁽³⁾	7,807	D	
Common Stock	10/29/2021		M		50,700	A	\$51.3	58,507	D	
Common Stock	10/29/2021		F		33,253	D	\$146.28	25,254	D	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisable	Expiration Date						Title
Options To Purchase Common Stock	\$39.87	10/29/2021		M			55,300	(4)	03/01/2026	Common Stock	55,300	\$0	0	D	
Sars (Stock Appreciation Rights)	\$51.3	10/29/2021		M			50,700	(5)	02/27/2025	Common Stock	50,700	\$0	0	D	

Explanation of Responses:

- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$143.90 to \$144.88. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$144.92 to \$145.92. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$145.93 to \$146.53. Full information regarding the number of shares sold at each separate price will be provided upon request of the Commission staff, CONMED, or a CONMED security holder.
- The stock options were granted under the Company's 2015 Amended and Restated Long-Term Incentive Plan and generally vest in equal amounts over a five year period.
- The stock appreciation rights ("SARs") were granted under the Company's 1999 Amended and Restated Long-Term Plan and generally vest in equal amounts (20%) over a five year period.

/s/ Sarah M. Olikier for Pat Beyer by Power of Attorney 11/02/2021
 ** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.